Early initiation of SGLT2 inhibitors after acute myocardial infarction.
作者信息
Hammer Andeas, Sossalla Samuel, Sulzgruber Patrick
机构信息
Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Weahringer Guertel 18-20, 1090 Vienna, Austria.
Medical Clinic I, Cardiology and Angiology, Justus-Liebig-University, Klinikstrasse 33, 35392 Giessen, Germany.
出版信息
Eur Heart J Cardiovasc Pharmacother. 2025 Jul 7;11(4):365-366. doi: 10.1093/ehjcvp/pvaf020.
Abstract
摘要
相似文献
1
Early initiation of SGLT2 inhibitors after acute myocardial infarction.
Eur Heart J Cardiovasc Pharmacother. 2025 Jul 7;11(4):365-366. doi: 10.1093/ehjcvp/pvaf020.
2
Sodium-Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Population-Based Investigation.
J Am Heart Assoc. 2023 Jul 18;12(14):e027824. doi: 10.1161/JAHA.122.027824. Epub 2023 Jul 8.
3
Short- and Long-Term Clinical Outcomes for Patients With Takotsubo Syndrome and Patients With Myocardial Infarction: A Report From the Swedish Coronary Angiography and Angioplasty Registry.
J Am Heart Assoc. 2021 Sep 7;10(17):e017290. doi: 10.1161/JAHA.119.017290. Epub 2021 Sep 1.
4
Nonculprit Vulnerable Plaques and Prognosis in Myocardial Infarction With Versus Without ST-Segment Elevation: A PROSPECT II Substudy.
Circulation. 2025 Jun 24;151(25):1767-1779. doi: 10.1161/CIRCULATIONAHA.124.071980. Epub 2025 Jun 23.
5
Differences in mortality and causes of death between STEMI and NSTEMI in the early and late phases after acute myocardial infarction.
PLoS One. 2021 Nov 17;16(11):e0259268. doi: 10.1371/journal.pone.0259268. eCollection 2021.
6
Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI.
J Am Coll Cardiol. 2024 Mar 5;83(9):904-914. doi: 10.1016/j.jacc.2024.01.002.
7
SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEART.
Lancet Reg Health Eur. 2024 Aug 21;45:101032. doi: 10.1016/j.lanepe.2024.101032. eCollection 2024 Oct.
8
Editor's Choice - Impact of initial hospital diagnosis on mortality for acute myocardial infarction: A national cohort study.
Eur Heart J Acute Cardiovasc Care. 2018 Mar;7(2):139-148. doi: 10.1177/2048872616661693. Epub 2016 Aug 29.
9
Epidemiology of acute myocardial infarction in the Italian CCU network: the BLITZ study.
Eur Heart J. 2003 Sep;24(18):1616-29. doi: 10.1016/s0195-668x(03)00278-1.
10
Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
Arch Cardiovasc Dis. 2014 Mar;107(3):149-57. doi: 10.1016/j.acvd.2014.01.010. Epub 2014 Mar 11.
本文引用的文献
1
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study.
Eur Heart J Cardiovasc Pharmacother. 2024 Aug 14;10(5):432-443. doi: 10.1093/ehjcvp/pvae045.
2
Empagliflozin after Acute Myocardial Infarction.
N Engl J Med. 2024 Apr 25;390(16):1455-1466. doi: 10.1056/NEJMoa2314051. Epub 2024 Apr 6.
3
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial.
Circulation. 2024 May 21;149(21):1627-1638. doi: 10.1161/CIRCULATIONAHA.124.069217. Epub 2024 Apr 6.
4
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023.
Eur Heart J Cardiovasc Pharmacother. 2024 May 4;10(3):219-244. doi: 10.1093/ehjcvp/pvae013.
5
Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure.
NEJM Evid. 2024 Feb;3(2):EVIDoa2300286. doi: 10.1056/EVIDoa2300286. Epub 2023 Nov 11.
6
Empagliflozin in acute myocardial infarction: the EMMY trial.
Eur Heart J. 2022 Nov 1;43(41):4421-4432. doi: 10.1093/eurheartj/ehac494.
Zotero 插件